What are the drug interactions between Auvelity (dextromethorphan/quinidine), Adderall (amphetamine/dextroamphetamine), and Abilify (aripiprazole)?

Drug Interactions Between Auvelity, Adderall, and Abilify

This combination carries significant risk for serotonin syndrome and requires extreme caution, close monitoring, and potentially dose adjustments or alternative treatment strategies. The primary concern is the serotonergic interaction between Auvelity's dextromethorphan component and Adderall's amphetamine, compounded by potential pharmacodynamic effects with Abilify.

Critical Serotonin Syndrome Risk

The combination of Auvelity (dextromethorphan/bupropion) with Adderall (amphetamine) creates a high-risk scenario for serotonin syndrome, a potentially life-threatening condition 1.

Mechanism of Interaction

• Dextromethorphan in Auvelity has serotonergic properties and acts as a serotonin reuptake inhibitor at supratherapeutic levels 2
• Amphetamines (Adderall) are explicitly listed as serotonergic drugs that require caution when combined with dextromethorphan 1
• The FDA label for Auvelity specifically warns about concomitant use with serotonergic drugs and states that if such use is clinically warranted, patients must be informed of increased serotonin syndrome risk and monitored for symptoms 3

Clinical Presentation to Monitor

Watch for serotonin syndrome symptoms within 24-48 hours after combining or adjusting doses 1:

• Mental status changes: confusion, agitation, anxiety
• Neuromuscular hyperactivity: tremors, clonus, hyperreflexia, muscle rigidity
• Autonomic hyperactivity: hypertension, tachycardia, arrhythmias, tachypnea, diaphoresis, shivering, vomiting, diarrhea
• Advanced symptoms: fever, seizures, arrhythmias, unconsciousness 1

If serotonin syndrome develops, immediately discontinue all serotonergic agents and initiate hospital-based supportive care with continuous cardiac monitoring 1, 3.

Aripiprazole (Abilify) Considerations

Potential Interaction with Amphetamine

• Aripiprazole acts as a dopamine D2 partial agonist and can attenuate the reinforcing and psychomotor stimulant effects of amphetamine 4, 5
• This interaction may reduce Adderall's therapeutic efficacy for ADHD, though one pediatric study showed the combination was tolerable and effective 6
• The American Geriatrics Society notes caution with combining three or more CNS agents (which would include this combination) due to increased fall risk 7

Serotonin Syndrome Risk with Aripiprazole

• A recent case report documented serotonin syndrome following aripiprazole reintroduction after dextromethorphan overdose, suggesting aripiprazole may contribute to serotonergic toxicity when combined with dextromethorphan 2
• This is particularly concerning given the presence of both dextromethorphan (in Auvelity) and amphetamine (in Adderall) in this combination

CYP2D6 Interaction

• Aripiprazole is metabolized by CYP2D6 8
• Bupropion (in Auvelity) is a CYP2D6 inhibitor that increases dextromethorphan bioavailability 3
• This may increase aripiprazole plasma levels, potentially increasing side effects including akathisia, sedation, or metabolic effects 8

Additional Safety Concerns

Drug-Drug Interaction Burden

• The American Geriatrics Society specifically added dextromethorphan/quinidine to their "use with caution" table due to increased risk of falls and drug-drug interactions 7
• While this refers to the quinidine formulation, the concern about multiple drug interactions remains relevant for Auvelity

Neuropsychiatric Effects

• Auvelity contains bupropion, which can cause neuropsychiatric symptoms including delusions, hallucinations, psychosis, and confusion 3
• Combining with amphetamine (which has similar stimulant properties) may increase risk of agitation, psychosis, or mania 3
• Screen for bipolar disorder history before using this combination, as both Auvelity and amphetamines can precipitate manic episodes 3

Cardiovascular Monitoring

• Both amphetamines and bupropion can increase blood pressure and heart rate 9
• Aripiprazole has minimal QT prolongation risk (0 ms mean prolongation) 10
• Monitor blood pressure regularly with this combination 3

Clinical Management Algorithm

If this combination is deemed clinically necessary:

1. Screen thoroughly before initiation 3:

   • History of bipolar disorder or risk factors
   • Current use of other serotonergic medications
   • Cardiovascular risk factors
   • History of seizures

2. Start with lowest effective doses 1:

   • Begin one medication at a time if possible
   • Increase doses slowly
   • Monitor intensively during first 24-48 hours after any dose change

3. Monitor closely for serotonin syndrome 1, 3:

   • Educate patient about symptoms
   • Schedule follow-up within first week
   • Consider more frequent monitoring during titration

4. Assess for reduced amphetamine efficacy 4:

   • Aripiprazole may antagonize amphetamine's therapeutic effects
   • May require dose adjustment of either medication

5. Monitor for neuropsychiatric symptoms 3:

   • Agitation, confusion, psychosis
   • Activation or manic symptoms
   • Discontinue if severe symptoms emerge

Alternative Considerations

Given the significant interaction risks, consider whether all three medications are truly necessary:

• Could Auvelity alone address both depression and ADHD symptoms (given its stimulant component)?
• Could aripiprazole be replaced with a non-dopaminergic mood stabilizer if needed for mood symptoms?
• Could a non-serotonergic ADHD medication (e.g., atomoxetine, guanfacine) replace Adderall?

The safest approach is to avoid this combination if possible, but if clinically essential, implement rigorous monitoring protocols and maintain the lowest effective doses of each agent 1, 7, 3.